drugset / Trial / NCT06051786

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis

NCT06051786

Phase 2 Completed 136 enrolled Synmosa Biopharma Corp.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Azelastine HCl-Fluticasone propionate Nasal Spray 137-50 mcg/spray compared to Dymista™ in patients with perennial allergic rhinitis

Timeline

Start
2020-08-20
Primary completion
2021-07-20
Completion
2021-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelastine Small molecule 137 ug Intranasal
Subject Fluticasone propionate Other / unclassified 50 ug Intranasal

Indications